Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015705 | 0.91 | RPS6KA3 (0.42) | CYP2A6RPS6KA3 | |
| SCHEMBL18015600 | 0.91 | TRPV1 (0.46) | TRPV1ABL1BCRTGFBR1METAP2 | |
| SCHEMBL19794448 | 0.91 | TRPV1 (0.46) | TRPV1ABL1BCRTGFBR1METAP2 | |
| SCHEMBL19794405 | 0.86 | NPC1 (0.40) | TRPV1ABL1BCRTGFBR1METAP2 | |
| SCHEMBL18015581 | 0.84 | TRPV1 (0.41) | TRPV1ABL1BCRTGFBR1METAP2 | |
| SCHEMBL21662242 | 0.84 | TRPV1 (0.41) | TRPV1ABL1BCRTGFBR1METAP2 | |
| SCHEMBL21662369 | 0.84 | TGFBR1 (0.43) | TRPV1ABL1BCRTGFBR1METAP2 | |
| SCHEMBL19831001 | 0.83 | TRPV1 (0.40) | TRPV1ABL1BCRTGFBR1METAP2 | |
| SCHEMBL19831193 | 0.83 | TRPV1 (0.40) | TRPV1ABL1BCRTGFBR1METAP2 | |
| SCHEMBL27344650 | 0.83 | TRPV1 (0.52) | TRPV1ABL1BCRCYP2A6TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | TRPV1 1461/4885ABL1 2613/4885BCR 4468/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | TRPV1 1114/4885ABL1 1770/4885BCR 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.